Ocular Therapeutix, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapies for diseases and conditions of the eye using its proprietary hydrogel platform technology in the United States. It markets ReSure Sealant, a hydrogel-based ophthalmic wound sealant to seal corneal incisions following cataract surgery. The company's lead product include DEXTENZA, which is in Phase III clinical trial for the treatment of post-surgical ocular inflammation and pain during cataract surgery, as well as for the treatment of allergic conjunctivitis; and in Phase II clinical trial for the treatment of inflammatory dry eye disease. It is also developing OTX-TP, which has completed Phase IIb clinical trial for glaucoma and ocular hypertension. In addition, the company has a pipeline of earlier stage punctum plug product candidates, including OTX-MP, which has completed a Phase I clinical trial evaluating safety and pharmacokinetics in patients during cataract surgery; and evaluates sustained-release injectable anti-VEGF drug depots for back-of-the-eye diseases. Ocular Therapeutix, Inc. was founded in 2006 and is headquartered in Bedford, Massachusetts.